Bin Dong1, Amar Bahadur Singh1, Chin Fung1, Kelvin Kan1, Jingwen Liu2. 1. Department of Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, USA. 2. Department of Veterans Affairs Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304, USA. Electronic address: Jingwen.Liu@va.gov.
Abstract
BACKGROUND: CETP inhibitors block the transfer of cholesteryl ester from HDL-C to VLDL-C and LDL-C, thereby raising HDL-C and lowering LDL-C. In this study, we explored the effect of CETP inhibitors on hepatic LDL receptor (LDLR) and PCSK9 expression and further elucidated the underlying regulatory mechanism. RESULTS: We first examined the effect of anacetrapib (ANA) and dalcetrapib (DAL) on LDLR and PCSK9 expression in hepatic cells in vitro. ANA exhibited a dose-dependent inhibition on both LDLR and PCSK9 expression in CETP-positive HepG2 cells and human primary hepatocytes as well as CETP-negative mouse primary hepatocytes (MPH). Moreover, the induction of LDLR protein expression by rosuvastatin in MPH was blunted by cotreatment with ANA. In both HepG2 and MPH ANA treatment reduced the amount of mature form of SREBP2 (SREBP2-M). In vivo, oral administration of ANA to dyslipidemic C57BL/6J mice at a daily dose of 50 mg/kg for 1 week elevated serum total cholesterol by approximately 24.5% (p < 0.05%) and VLDL-C by 70% (p < 0.05%) with concomitant reductions of serum PCSK9 and liver LDLR/SREBP2-M protein. Finally, we examined the in vitro effect of two other strong CETP inhibitors evacetrapib and torcetrapib on LDLR/PCSK9 expression and observed a similar inhibitory effect as ANA in a concentration range of 1-10 μM. CONCLUSION: Our study revealed an unexpected off-target effect of CETP inhibitors that reduce the mature form of SREBP2, leading to attenuated transcription of hepatic LDLR and PCSK9. This negative regulation of SREBP pathway by ANA manifested in mice where CETP activity was absent and affected serum cholesterol metabolism. Published by Elsevier Ireland Ltd.
BACKGROUND:CETP inhibitors block the transfer of cholesteryl ester from HDL-C to VLDL-C and LDL-C, thereby raising HDL-C and lowering LDL-C. In this study, we explored the effect of CETP inhibitors on hepatic LDL receptor (LDLR) and PCSK9 expression and further elucidated the underlying regulatory mechanism. RESULTS: We first examined the effect of anacetrapib (ANA) and dalcetrapib (DAL) on LDLR and PCSK9 expression in hepatic cells in vitro. ANA exhibited a dose-dependent inhibition on both LDLR and PCSK9 expression in CETP-positive HepG2 cells and human primary hepatocytes as well as CETP-negative mouse primary hepatocytes (MPH). Moreover, the induction of LDLR protein expression by rosuvastatin in MPH was blunted by cotreatment with ANA. In both HepG2 and MPH ANA treatment reduced the amount of mature form of SREBP2 (SREBP2-M). In vivo, oral administration of ANA to dyslipidemic C57BL/6J mice at a daily dose of 50 mg/kg for 1 week elevated serum total cholesterol by approximately 24.5% (p < 0.05%) and VLDL-C by 70% (p < 0.05%) with concomitant reductions of serum PCSK9 and liver LDLR/SREBP2-M protein. Finally, we examined the in vitro effect of two other strong CETP inhibitors evacetrapib and torcetrapib on LDLR/PCSK9 expression and observed a similar inhibitory effect as ANA in a concentration range of 1-10 μM. CONCLUSION: Our study revealed an unexpected off-target effect of CETP inhibitors that reduce the mature form of SREBP2, leading to attenuated transcription of hepatic LDLR and PCSK9. This negative regulation of SREBP pathway by ANA manifested in mice where CETP activity was absent and affected serum cholesterol metabolism. Published by Elsevier Ireland Ltd.
Authors: Mark J Graham; Kristina M Lemonidis; Charles P Whipple; Amuthakannan Subramaniam; Brett P Monia; Stanley T Crooke; Rosanne M Crooke Journal: J Lipid Res Date: 2007-01-22 Impact factor: 5.922
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Rajesh Krishna; Matt S Anderson; Arthur J Bergman; Bo Jin; Marissa Fallon; Josee Cote; Kim Rosko; Cynthia Chavez-Eng; Ryan Lutz; Daniel M Bloomfield; Maria Gutierrez; James Doherty; Fredrick Bieberdorf; Jeffrey Chodakewitz; Keith M Gottesdiener; John A Wagner Journal: Lancet Date: 2007-12-08 Impact factor: 79.321
Authors: John S Millar; Gissette Reyes-Soffer; Patricia Jumes; Richard L Dunbar; Emil M deGoma; Amanda L Baer; Wahida Karmally; Daniel S Donovan; Hashmi Rafeek; Laura Pollan; Junichiro Tohyama; Amy O Johnson-Levonas; John A Wagner; Stephen Holleran; Joseph Obunike; Yang Liu; Rajasekhar Ramakrishnan; Michael E Lassman; David E Gutstein; Henry N Ginsberg; Daniel J Rader Journal: J Clin Invest Date: 2015-05-11 Impact factor: 14.808
Authors: Sam J L van der Tuin; Susan Kühnast; Jimmy F P Berbée; Lars Verschuren; Elsbet J Pieterman; Louis M Havekes; José W A van der Hoorn; Patrick C N Rensen; J Wouter Jukema; Hans M G Princen; Ko Willems van Dijk; Yanan Wang Journal: J Lipid Res Date: 2015-09-04 Impact factor: 5.922
Authors: Mark Gormley; James Yarmolinsky; Tom Dudding; Kimberley Burrows; Richard M Martin; Steven Thomas; Jessica Tyrrell; Paul Brennan; Miranda Pring; Stefania Boccia; Andrew F Olshan; Brenda Diergaarde; Rayjean J Hung; Geoffrey Liu; Danny Legge; Eloiza H Tajara; Patricia Severino; Martin Lacko; Andrew R Ness; George Davey Smith; Emma E Vincent; Rebecca C Richmond Journal: PLoS Genet Date: 2021-04-22 Impact factor: 5.917